Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient

The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors. Furthermore, the BRAF/MEK combination has shown further improvement in clinical outcomes in advanced and in adjuvant melanoma patients. In low-grade ovarian tumors, BRAF inhibitor use has been also proposed. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Anchisi, Sandro, Wolfer, Anita, Bisig, Bettina, Missiglia, Edoardo, Tiab, Amine, Kamel, Ehab Mohamed, Michielin, Olivier, Coukos, George, Homicsko, Krisztian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Journal Club
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054366/
https://www.ncbi.nlm.nih.gov/pubmed/36967525
http://dx.doi.org/10.1080/15384047.2023.2193116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054366/
https://www.ncbi.nlm.nih.gov/pubmed/36967525
http://dx.doi.org/10.1080/15384047.2023.2193116

Ejemplares similares